HK Inno.N Corp.

HK Inno.N Corp. is a South Korean pharmaceutical company founded in 1984 and headquartered in Cheongju-si. It offers prescription drugs across areas including antibiotics, anemia and hemodialysis, diabetes, hypertension and dyslipidemia, gastrointestinal conditions, oncology, and nutrition. The company also provides health and beverage products, active pharmaceutical ingredients, and beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. Its products are exported to Japan, Southeast Asia, Latin America, Europe, and the Middle East, and it has a joint research and development agreement with Nextgen Bioscience for NXC680, a candidate compound for idiopathic pulmonary fibrosis.